Conv. Plasma
Nigella Sativa
Peg.. Lambda

All fluvoxamine studies
Meta analysis
Home COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Oxygen therapy -2% Improvement Relative Risk Hospitalization -22% Fluvoxamine  EFFaCo  EARLY TREATMENT  RCT Is early treatment with fluvoxamine beneficial for COVID-19? RCT 327 patients in Thailand (June 2021 - February 2022) Trial underpowered to detect differences Siripongboonsitti et al., Int. J. Infe.., Jun 2023 Favors fluvoxamine Favors control

Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study)

Siripongboonsitti et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2023.06.018, EFFaCo
Jun 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 327 outpatients in Thailand, showing no significant difference with 50mg fluvoxamine bid added to favipiravir. Authors note that trials showing benefit mostly used 100mg bid.
risk of oxygen therapy, 1.9% higher, RR 1.02, p = 1.00, treatment 4 of 162 (2.5%), control 4 of 165 (2.4%).
risk of hospitalization, 22.2% higher, RR 1.22, p = 0.77, treatment 6 of 162 (3.7%), control 5 of 165 (3.0%), day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Siripongboonsitti et al., 29 Jun 2023, Randomized Controlled Trial, Thailand, peer-reviewed, 9 authors, study period 26 June, 2021 - 22 February, 2022, EFFaCo trial.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study)
M.D. M.Sc Taweegrit Siripongboonsitti, Mullika Buttakosa B.Sc Gaidganok Sornsamdang, M.D Teerapat Ungtrakul, M.D Kriangkrai Tawinprai, B.Sc Tararin Nimmol, B.Sc Mullika Buttakosa, MD Tanadul Jarrusrojwuttikul, M.D Phumin Silapant, M.D Nithi Mahanonda
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Bast, Tang, Dahn, Palacio, Increased risk of hospitalisation and death with the delta variant in the USA, Lancet Infect Dis, doi:10.1016/s1473-3099
Bernal, Da Silva, Musungaie, Kovalchuk, None
Bramante, Huling, Tignanelli, Buse, Liebovitz et al., Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2201662
Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
Chen, Huang, Cheng, Wu, Chen et al., Favipiravir versus arbidol for COVID-19: a randomized clinical trial, MedRxiv, doi:10.1101/2020.03.17
Chuah, Chow, Hor, Cheng, Ker et al., Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial, Clin Infect Dis, doi:10.1093/cid/ciab962
Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1844
Fung, Liu, The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy induction in cells infected with coronavirus infectious bronchitis virus, Virology, doi:10.1016/j.virol.2019.05.002
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, doi:10.2183/pjab.93.027
Guo, Harari, Chernecki, Thorlund, Forrest, Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials, Am J Trop Med Hyg, doi:10.4269/ajtmh.21-1310
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials, Scientific reports, doi:10.1038/s41598-021-90551-6
Hoertel, Sánchez-Rico, De La Muela, Abellán, Blanco et al., Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France, Biol Psychiatry Glob Open Sci, doi:10.1016/j.bpsgos.2021.12.007
Homolak, Kodvanj, Widely available lysosome targeting agents should be considered as potential therapy for COVID-19, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106044
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clinical Infectious Diseases, doi:10.1093/cid/ciaa1176
Lee, Vigod, Bortolussi-Courval, Hanula, Boulware et al., Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis, JAMA Netw Open, doi:10.1001/jamanetworkopen.2022.6269
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial, Jama, doi:10.1001/jama.2020.22760
Mccarthy, Naggie, Boulware, Lindsell, Stewart et al., Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial, doi:10.1101/2022.10.17.22281178
Németh, Szûcs, Vitrai, Juhász, Németh et al., Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective casecontrol study, Ideggyogy Sz, doi:10.18071/isz.74.0389
Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants, JAMA Netw Open, doi:10.1001/jamanetworkopen.2021.33090
Reis, Santos Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health, doi:10.1016/s2214-109x(21)00448-4
Reis, Santos, Silva, Silva, Thabane et al., Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial, Ann Intern Med, doi:10.7326/m22-3305
Reyes, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med, doi:10.1056/NEJMoa2116044
Schlienger, Meier, Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?, Am J Cardiovasc Drugs, doi:10.2165/00129784-200303030-00001
Seftel, Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infect Dis, doi:10.1093/ofid/ofab050
Seo, Kim, Bae, Park, Chung et al., Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial, Infect Chemother, doi:10.3947/ic.2021.0142
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virology journal, doi:10.1186/s12985-020-01412-z
Sukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19, Front Pharmacol, doi:10.3389/fphar.2021.652688
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop